Evidence map›Paper›PMID 35167133›Full record

Trial reportClinical and experimental dermatology2022

Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis.

Simon G Danby, Paul V Andrew, Rosie N Taylor, Linda J Kay, John Chittock, Abigail Pinnock, Intisar Ulhaq, Anna Fasth, Karin Carlander, Tina Holm and 1 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03901144 (A Phase 2 Randomised Controlled Trial of a NOVel Moisturiser for Atopic Dermatitis), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03901144 phase2completednot on this map

A Phase 2 Randomised Controlled Trial of a NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier in Adults With a Predisposition to a Skin Barrier Defect

TypeinterventionalSponsorACO Hud Nordic ABRan2019 to 2019Enrolled50ConditionsDermatitis, AtopicArms2% urea/20% glycerol cream, Miniderm® 20% cream, Diprobase® cream
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 60 citations in OpenAlex.

  1. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Biologically Active Sheep Colostrum for Topical Treatment and Skin Care.International journal of molecular sciences · 2024
    Article
  12. Article
  13. Topical steroids or emollients: does order matter?Archives of dermatological research · 2024
    Review
  14. Skin microbiota: pathogenic roles and implications in atopic dermatitis.Frontiers in cellular and infection microbiology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Targeting Skin Barrier Function in Atopic Dermatitis.The journal of allergy and clinical immunology. In practice · 2023
    Article
  19. Patient-Centric Design of Topical Dermatological Medicines.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Simon G DanbySheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.ORCID https://orcid.org/0000-0001-7363-140X
Paul V AndrewSheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.
Rosie N TaylorStatistical Services Unit, University of Sheffield, Sheffield, UK.
Linda J KaySheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.
John ChittockSheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.ORCID https://orcid.org/0000-0002-1595-7441
Abigail PinnockSheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.
Intisar UlhaqSheffield Children's Hospital, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Anna FasthPerrigo Nordic, Kista, Stockholm, Sweden.
Karin CarlanderPerrigo Nordic, Kista, Stockholm, Sweden.
Tina HolmPerrigo Nordic, Kista, Stockholm, Sweden.
Michael J CorkSheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK.ORCID https://orcid.org/0000-0003-4428-2428
University of Sheffield · GBPerrigo (Sweden) · SERoyal Hallamshire Hospital · GBSheffield Children's NHS Foundation Trust · GB

Funding

Perrigo Nordic N/A
6 · The paper itself

Abstract

backgroundEczema (atopic dermatitis; AD) is a very common itchy skin condition affecting 1 in 5 children and up to 1 in 10 adults worldwide. The skin of eczema sufferers is prone to redness, irritation and dryness because it does not form an effective barrier, i.e. the ability of the skin to stop irritants, allergens and microorganisms getting into the body. Skin barrier dysfunction is a hallmark of AD. The regular and liberal (600 g/week for an adult) use of emollients is recommended for all patients with eczema), even between episodes of itching and redness, to soften and soothe the skin. In England alone, almost 9 million prescriptions for emollient creams were issued in 2018, at a cost of over £50 million. Despite this widespread use, relatively little is known about how commonly prescribed emollient creams affect the skin's barrier, and thus the role of moisturizers in AD development and progression remains unclear. We set out to compare three different types of emollient cream and a no-treatment control.

aimTo compare the barrier-strengthening properties of a new moisturizer containing urea and glycerol (urea-glycerol cream; UGC), with those of a glycerol-containing moisturizer (glycerol cream; GC), a simple paraffin cream (PC) with no humectant, and a no-treatment control (NTC).

methodsThis was an observer-blinded prospective Phase 2 within-subject multilateral single-centre randomized controlled trial in adults with AD (Clinical Trials #NCT03901144). The intervention involved 4 weeks of treatment, twice daily, with the three products applied to one of four areas on the forearms the (the fourth area was the untreated control, randomized allocation). Skin properties [dryness, transepidermal water loss (TEWL), hydration and natural moisturizing factor (NMF) levels] were assessed before, during and after treatment to see what happened to the skin's barrier. The primary outcome was skin sensitivity to the irritant sodium lauryl sulfate (SLS) after treatment. We performed tests on the skin before and after treatment to see what happened to the skin's barrier.

resultsIn total, 49 patients were randomized, completed treatment and included in the analysis. UGC significantly reduced the response to SLS as indicated by a reduction in TEWL compared with NTC (-9.0 g/m

conclusionThe study showed that not all emollient creams for eczema are equal. The simple paraffin-based emollient, which represents the most widely prescribed type of emollient cream in England, had no effect on the skin's barrier and reduced the skin's NMF. UGC markedly improved the skin's barrier and protected against irritation. GC performed better than PC, but not as well as UGC. UGC strengthened the skin barrier through a mechanism involving increased NMF levels in the skin, and imparted protection from SLS-induced irritation. By helping correct a major pathophysiological process, UGC has the potential to improve the long-term control of AD. The results show that different emollient creams have different effects on our skin, and only certain types have the ability to improve the skin's barrier and protect against irritants that trigger eczema.

Indexed as

Dermatitis, AtopicEczemaAdultChildEmollientsGlycerolHumansIrritantsParaffinProspective StudiesPruritusSkin CreamUreaWater Loss, InsensibleEmollientsGlycerolIrritantsParaffinUrea

Identifiers

PMID35167133
PMCPMC9322554
OpenAlexW4213079317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.